ASCO GU 2022 | A lack of efficacy in VEGF inhibition for the treatment of patients with bladder cancer

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, and University of Paris-Saclay, Gif-sur-Yvette, France, discusses the exploration of VEGF inhibitors in patients with bladder cancer. Unfortunately, most investigations of VEGF inhibition in this patient population have been unsuccessful, demonstrating insignificant progression-free survival (PFS) and overall survival (OS) rates. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.